A Study of JNJ-87890387 for Advanced Solid Tumors

Part of paid clinical trials in Grand Rapids, Michigan.

Sponsor
Janssen Research & Development, LLC
Study ID
NCT06178614
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumors
  • Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JNJ-87890387 — DRUG
    JNJ-87890387 will be administered.

Study Details

The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).

Key Dates

Start date
Dec 14, 2023
Status verified
Jun 2026
Primary completion
Mar 16, 2027
Completion
Feb 7, 2029

Study Design

Enrollment
200 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: JNJ-87890387
    In Part 1 (Dose escalation) participants will receive JNJ-87890387. The dose will be escalated sequentially until the recommended phase 2 dose (RP2D) regimen(s) have been identified. In Part 2 (Dose expansion), participants will receive JNJ-87890387 at the RP2D regimen(s) determined in Part 1.

Primary Outcome Measure

Part 1: Number of Participants with Dose Limiting Toxicity (DLTs) [ Time Frame: Up to first 21 days after administration of the first full treatment dose ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Start MidwestGrand RapidsMichigan49546-
Sarah Cannon Research InstituteNashvilleTennessee37203-

Find similar trials in Grand Rapids, MI

By research site
Start Midwest· Grand Rapids, MISarah Cannon Research Institute· Nashville, TN

Related Studies